HTB homepage • Conference reports • Articles by subject • Subscribe 24 July 2019 Contents Editorial HTB 24 July 2019 online: first reports from IAS 2019 Special reports Fit for purpose 2019 – PDF Conference reports 10th IAS Conference on HIV Science (IAS 2019) in Mexico City Dolutegravir neural tube defect risk declines but still slightly higher than with other antiretrovirals WHO recommends dolutegravir-based ART regimens for all High rates of viral suppression with low dose efavirenz in pregnant Zambian women First viral load results for capsid inhibitor GS-6207: mean –2.2 log reduction at day 10 Islatravir (MK-8591) with doravirine plus lamivudine: 24 week results Dual therapy with islatravir (MK-8591) plus doravirine: 24 week results as switch strategy Fostemsavir: 96-week follow-up in people with multi-drug resistance Dolutegravir/lamivudine dual therapy non-inferior to triple ART at week-96 Switching to dolutegravir/lamivudine dual therapy is non-inferior to TAF-based triple therapy at week-48 in TANGO study Islatravir (MK-8591) implant sustains HIV PrEP protection for more than one year PDFs 24 July 2019 vol 20 no 9 HTB homepage • Conference reports • Articles by subject • Subscribe
